Levosimendan versus dobutamine in acute decompensated heart failure: systematic review and meta-analysis of randomised controlled trials
Levosimendan reduced short-term mortality and hospital stay compared with dobutamine in patients with ADHF, although the certainty of evidence was moderate for mortality and very low for hospital stay. Larger trials are needed to confirm these findings.
Authors
- Hugo Parente (ORCID: https://orcid.org/0009-0002-3419-6366)
- Carlos Magliano
- Matheus Fernandes de Oliveira (ORCID: https://orcid.org/0000-0003-1123-7583)
- João Vitor Fazzio de Andrade Cordeiro
- Diamantino Salgado
- Laura Moita Sforza
Institutions
- Universidade Federal do Rio de Janeiro (BR)
- D’Or Institute for Research and Education (BR)
- Instituto Nacional de Cardiologia (BR)
Publication Details
- Journal
- Heart
- Published
- 2025-11-12
- DOI
- https://doi.org/10.1136/heartjnl-2025-326744
- Primary Topic
- Heart Failure Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00